Is NTLA overvalued right now?
A stock is overvalued when its market price sits above a reasonable fair value range. Use the live snapshot on this page for NTLA, then validate with fundamentals and peer multiples.
Intellia Therapeutics, Inc. (NTLA) is currently Undervalued by 128.99%
Instant valuation answer
Intellia Therapeutics, Inc. (NTLA) appears undervalued by approximately 128.99% based on our live valuation percent and intrinsic value estimate derived from DCF, P/E Multiple, and P/S Multiple models. Valuation can still differ across analyst models, growth expectations, and risk assumptions.
- Upside (live) 128.99% (from live valuation API)
- Confidence (live) 9.5/10 (Very High)
Confidence Score is based on the magnitude of upside or downside vs intrinsic value.
Fair value estimate
Unlock fair valueCurrent price
$17.43
Stock valuation checker
Search our company database (same as the site header). Choose a result or type a ticker and press Check valuation.
Explore Our Valuation Calculators
Why is Intellia Therapeutics, Inc. overvalued or undervalued?
Based on intrinsic value, Intellia Therapeutics, Inc. (NTLA) looks priced ahead of a cash-flow-based fair value that blends growth, reinvestment needs, and a risk-adjusted discount rate.
Compared to historical valuation, today’s multiple exceeds the range implied by the company’s own five-year average—suggesting the market is more optimistic than its own past pricing of similar fundamentals.
Market expectations embedded in the price imply a demanding bar for execution: revenue cadence, margin stability, and capital returns would need to accelerate to justify a sustained premium versus fair value.
Key metrics
- P/E ratio
- 29.1x
- Revenue growth (TTM y/y)
- 16%
- Profit margin
- 24.0%
- Fair value (model)
- Unlock
Frequently asked questions — NTLA
What is Intellia Therapeutics, Inc.'s intrinsic value?
Our DCF, P/E Multiple, and P/S Multiple models estimate whether NTLA trades above or below fair value. At $17.43, Intellia Therapeutics, Inc. currently looks undervalued on this snapshot. Tickerplace Pro unlocks the full dollar fair value estimate.
How is Intellia Therapeutics, Inc.'s intrinsic value calculated?
Tickerplace calculates NTLA's fair value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We compare the resulting intrinsic value estimate to the live market price to flag undervalued or overvalued positioning.
Is NTLA undervalued right now?
Based on our 2026 valuation models, Intellia Therapeutics, Inc. (NTLA) appears undervalued at $17.43 with about 129.0% upside to fair value. Treat this as a screen—verify fundamentals on the company profile.
Related companies — valuation
Peers for NTLA: open their overvalued / undervalued view.